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Introduction: Group comparisons demonstrate greater visuospatial and memory deficits and temporoparietal-predominant
degeneration on neuroimaging in patients with corticobasal syndrome (CBS) found to have Alzheimer’s disease
(AD) pathology versus those with underlying frontotemporal lobar degeneration (FTLD). The value of these features in
predicting underlying AD pathology in individual patients is unknown. The goal of this study is to evaluate the utility of
modified clinical criteria and visual interpretations of magnetic resonance imaging (MRI) and fluorodeoxyglucose
positron emission tomography (FDG-PET) for predicting amyloid deposition (as a surrogate of Alzheimer’s disease
neuropathology) in patients presenting with CBS.
Methods: In total, 25 patients meeting CBS core criteria underwent amyloid (Pittsburgh compound B; PIB) PET
scans. Clinical records, MRI, and FDG scans were reviewed blinded to PIB results. Modified clinical criteria were
used to classify CBS patients as temporoparietal variant CBS (tpvCBS) or frontal variant CBS (fvCBS). MRI and FDG-PET
were classified based on the predominant atrophy/hypometabolism pattern (frontal or temporoparietal).
Results: A total of 9 out of 13 patients classified as tpvCBS were PIB+, compared to 2out of 12 patients classified as
fvCBS (P < 0.01, sensitivity 82%, specificity 71% for PIB+ status). Visual MRI reads had 73% sensitivity and 46% specificity
for PIB+ status with moderate intra-rater reliability (Cohen’s kappa = 0.42). Visual FDG reads had higher sensitivity (91%)
for PIB+ status with perfect intra-rater reliability (kappa = 1.00), though specificity was low (50%). PIB results were
confirmed in all 8 patients with available histopathology (3 PIB+ with confirmed AD, 5 PIB- with FTLD).
Conclusions: Splitting CBS patients into frontal or temporoparietal clinical variants can help predict the likelihood
of underlying AD, but criteria require further refinement. Temporoparietal-predominant neuroimaging patterns are
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Corticobasal syndrome (CBS) is a neurodegenerative
syndrome characterized by asymmetric rigidity, apraxia,
dystonia, loss of voluntary limb control and cortical
sensory loss [1-3]. Although CBS was once thought to
reliably predict neuropathological findings of corticoba-
sal degeneration (CBD), autopsy studies have revealed
diverse pathological substrates for CBS, including pro-
gressive supranuclear palsy, Lewy body disease (LBD),
frontotemporal lobar degeneration with TDP-43 inclu-
sions (FTLD-TDP) and prion disease. Alzheimer’s disease
(AD) is found to be the primary underlying pathology in
approximately 25% of patients [4-8]. Identifying patients
with underlying AD during life is important because
they may benefit from symptomatic therapies and future
disease modifying agents. Patients with primary or
co-morbid AD may also be excluded from clinical trials
of biologically specific therapies in CBS in order to avoid
potential confounds of amyloid co-pathology.
As a group, patients with CBS due to AD (CBS-AD)
show greater episodic memory loss and visuospatial
deficits, whereas CBS patients due to FTLD pathology
(CBS-FTLD) show more behavioral changes, executive
dysfunction, non-fluent aphasia and orobuccal apraxia
[7,9-11], although these differences are not always
found [12]. On neuroimaging, CBS-AD patients dem-
onstrate greater temporoparietal involvement, while
CBS-FTLD patients display greater brainstem atrophy
[7,10,11]. Both groups show atrophy in a common
peri-rolandic network thought to underlie the core
CBS syndrome [7,10,11]. Similar group-level differ-
ences in clinical features and atrophy patterns were re-
cently reported using amyloid imaging as a surrogate
for AD pathology [13]. The value of these observations
for predicting pathology in individual patients has not
been investigated.
In this study, we evaluated whether splitting CBS
into frontal (fvCBS) and temporoparietal-predominant
variants (tpvCBS) based on clinical features could dis-
tinguish patients with FTLD versus AD pathology.
Although an expert international group recently pro-
posed new diagnostic criteria for CBD [14], the new
criteria were published after completion of the chart
review phase of our study such that we were not able
to test their reliability prospectively and in blinded
fashion. Because the majority of our autopsied patients
were included in a previous report that demonstrated
group-level differences between CBS-AD and CBS-FTLD
[7], we tested the predictive value of CBS variants in an
independent cohort of patients who underwent positron
emission tomography (PET) imaging with the beta-
amyloid ligand Pittsburgh compound B (PIB-PET) as a
surrogate marker of AD pathology [15]. Eight patients
included in the study have subsequently undergonepathologic examination. Although amyloid PET scans
may ultimately be the optimal imaging modality for de-
tecting AD pathology in CBS patients, this technology
is not yet widely available or reimbursed by third-party
payers. We, therefore, sought to determine whether
more accessible neuroimaging modalities, such as struc-
tural magnetic resonance imaging (MRI) and fluo-
rodeoxyglucose PET (FDG-PET), could, individually,
predict PIB-PET status. Finally, we investigated whether
combinations of clinical and imaging features could
further improve our ability to distinguish CBS-AD and
CBS-FTLD during life.
Methods
Standard protocol approvals, registrations, and patient
consents
All aspects of the study were approved by the institu-
tional review boards at the University of California San
Francisco (UCSF), UC Berkeley, Lawrence Berkeley
National Laboratory (LBNL), UC Los Angeles, and
Mayo Clinic Jacksonville. All patients or surrogates
provided written informed consent.
Participants
Patients
A search in the UCSF Memory and Aging Center data-
base identified 31 patients with a clinical diagnosis of
CBS who underwent PIB-PET between 2005 and 2013.
One patient was excluded due to an incomplete PIB-
PET scan and four were excluded because chart review
(by SJS, see below) revealed that they did not meet core
CBS research criteria (Table 1). One patient was ex-
cluded because the rater knew the patient and could
not be blinded. All patients included in the study
underwent a history and examination by a neurologist
with expertise in neurodegenerative disease, cognitive
testing by a neuropsychologist and a structural MRI
and/or FDG-PET.
Controls
Age-matched cognitively-normal controls (NC) recruited
from the community who had undergone both FDG-
PET and PIB-PET as part of aging research studies were
used as imaging controls [17]. To try to best match our
patient group, we selected a comparably sized group of
the youngest available controls with FDG data. Controls
were not selected based on PIB results – however, 3/26
were PIB+ applying a global quantitative threshold of
distribution volume ratios (DVR) ≥1.20 [18]. On retro-
spective assessment of FDG scans, none of these individ-
uals showed an AD-like pattern or other qualitatively
apparent abnormalities.
A total of 25 CBS patients and 26 normal controls
were included in further analyses.
Table 1 Modified corticobasal syndrome criteria
I. CBS: core criteria
Inclusion criteria (1 plus 2)
1. Progressive course
2. At least three of the following:
a. Parkinsonism (bradykinesia or rigidity)
b. Dystonia
c. Myoclonus
d. Impairment in voluntary limb control (alien limb)
e. Cortical sensory deficit (symmetric/asymmetric)
Exclusion criteria (all must be negative)
a. Visual hallucinations
b. REM sleep behavior disorder
c. Cerebellar ataxia
d. Prominent autonomic dysfunction
e. Fluctuations in alertness
f. Prominent rest tremor
II. CBS- frontal variant:
Inclusion criteria (meets core plus one of the following must be positive)
1. Agrammatism, non-fluent speech or motor speech deficits
2. Apathy, disinhibition or loss of empathy
3. Apraxia primarily affecting lower extremities
4. Prominent executive dysfunction greater than memory or
visuospatial impairment
III. CBS- temporoparietal variant:
Inclusion criteria (meets core plus one of the following must be positive)
1. Logopenic aphasia [16]
2. Elements of Gerstmann or Balint syndrome
3. Episodic memory or visuospatial impairment greater than executive
dysfunction
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Core and variant criteria
Core CBS clinical criteria were modified from our previ-
ously published report [19]. We defined specific clinical
features associated with fvCBS or tpvCBS (Table 1). The
criteria were based on our previous group-level analysis
[7], review of the literature, and were agreed on by clini-
cians experienced in CBS evaluation (SJS, SEL, ALB, KR,
JHK, WWS, MGT, BLM, GDR).
Blinded chart review
A neurologist (SJS) who was blinded to imaging results
reviewed clinical summaries and cognitive test results
from each patient’s UCSF evaluation. Each diagnostic
criterion was noted as present or absent for the patient’s
initial visit. Based on the criteria (Table 1), patients were
classified as fvCBS or tpvCBS. If a patient met criteria
for both variants, the rater used her overall impression to
assign one variant. All diagnoses were given a confidencerating using a 5-point scale: 1-highest confidence of
fvCBS, 2-moderate confidence of fvCBS, 3-equivocal
rating, 4-moderate confidence tpvCBS, 5-highest confi-
dence of tpvCBS.
Genetics and neuropathology
APOE genotyping was performed on patients and con-
trols (Table 2). Five patients had autopsies performed
using previously published protocols [7] and one had a
biopsy at UCSF. One autopsy was performed at Mayo
Clinic Jacksonville and one was performed at UCLA
using previously published methods [10,20]. Consensus
criteria were used for the pathological diagnosis of AD
[21], CBD [22] and LBD [23].
Image acquisition
Patients underwent high-resolution (1 mm3) T1-weighted
structural MR imaging at UCSF (3 T scanner) or at the
San Francisco Veterans Affairs Medical Center (1.5 T or
4 T scanner), as previously described [24-26]. MRI scans
were acquired within one year of PET scan. PET imaging
with [11C]PiB and [18F]FDG were performed on a Siemens
ECAT EXACT HR (N= 22) or Siemens Biograph PET/CT
Truepoint 6 (N = 1) scanner at LBNL. Image preprocess-
ing and analysis were performed using Statistical Paramet-
ric Mapping version 8 [27]. FDG-PET frames for each
subject were summed and standard uptake volume ratios
(SUVR) were normalized to mean activity in the pons.
PIB-PET DVR were calculated with Logan graphical ana-
lysis [28] using the grey matter cerebellum time-activity
curve as reference tissue input function [29]. Mean FDG
SUVR from ‘frontal,’ ‘temporoparietal’ and ‘common’ (the
latter reflecting peri-rolandic regions affected across CBS
variants) cortical regions of interest (ROIs) were extracted
in template space using the Automated Anatomical
Labeling (AAL) atlas space as previously described
[30]. The ROIs (separately for left and right hemi-
spheres and combined) were created using the AAL
Atlas [31] and included: frontal cortex (composed of AAL
regions superior frontal gyrus, middle frontal gyrus, infer-
ior frontal gyrus, operculum, olfactory gyrus, gyrus rectus,
insula, anterior cingulate), temporoparietal cortex (AAL
regions posterior cingulate, superior parietal lobe, inferior
parietal lobe, supramarginal gyrus, angular gyrus, pre-
cuneus, superior temporal gyrus, middle temporal gyrus,
inferior temporal gyrus) and CBS common regions (AAL
regions precentral gyrus, postcentral gyrus, supplementary
motor area, paracentral lobule).
Image visual rating
A neurologist (SJS) visually rated MRI scans as either
‘frontal variant’ (fv) or ‘temporoparietal variant’ (tpv)
corresponding to an atrophy pattern greatest in frontal
regions or temporoparietal regions, respectively (see
Table 2 Demographics
Syndromic diagnosis CBS-PIB + (number = 11) CBS-PIB - (number = 14) NC (number = 26) P Post hoc
Age at PET 66.9 ± 5.5 65.8 ± 8.8 70.2 ± 2.9 0.054
Age at MRI 67.2 ± 5.2 66.1 ± 9.3 (n = 13) 0.110
Age at first clinic visit 65.6 ± 9.1 66.5 ± 5.1 n/a 0.750
Male: Female 6:5 6:8 14:12 0.810
Education, years 15.7 ± 2.2 15.8 ± 2.4 17.3 ± 2.0 0.620
MMSE 22.9 ± 6.3 22.4 ± 6.9 29.2 ± 1.2 0.0001 CBS-PIB+ vs NC P <0.05,
CBS-PIB- vs NC P <0.01
CDR 0.7 ± 0.5 0.9 ± 0.6 n/a 0.830
CDR-SB 4.7 ± 3.2 3.7 ± 2.6 n/a 0.400
APOE4 (0,1,2) 4, 6, 0 (n = 10) 9, 1, 0 (n = 10) 17, 8, 1 0.066 CBS-PIB+ vs CBS-PIB- P < 0.05
CBS-PIB+, Corticobasal syndrome positive for Pittsburgh compound B; CBS-PIB-, Corticobasal syndrome negative for Pittsburgh compound B; CDR, Clinical Dementia
Rating; CDR-SB, Clinical Dementia Rating sum of boxes; MMSE, Mini-mental State Examination; n/a, not applicable; NC, normal control. Data are mean ± standard deviation.
Sha et al. Alzheimer's Research & Therapy  (2015) 7:8 Page 4 of 12Figure 1 for typical atrophy patterns). Each scan was
given a confidence rating using the same scale described
for clinical diagnosis. [18F]FDG PET scans were visually
rated at a separate session in an analogous manner (SJS)
blinded to diagnosis and PIB-PET status (Figure 1 for
typical hypometabolic patterns). Intra-rater reliability
was ascertained by re-reading randomly determined sub-
sets of 10 MRI and 10 FDG-PET scans at a separate
sitting, blinded to prior rating.
FDG-PET quantitative rating
Quantitative ratings of FDG-PET were performed to
compare the qualitative interpretations performed in
routine clinical practice with more rigorous quantitative
approaches to see if the latter provide added value. FDG
uptake in each ROI was assigned a Z score based on re-
gional uptake in the normal control group. ClassificationFigure 1 Typical FDG PET metabolic patterns and MRI atrophy patter
positron emission tomography.was determined by the lowest ROI Z score for each
patient (for example, tpv was classified if Z score was
lower in temporoparietal regions than in frontal region).
The difference in Z scores was calculated as the Z
difference = Z (frontal) – Z (temporoparietal) [18]. To
assess for asymmetry, lateralization indices (LIs) were
calculated to compare left- and right-sided tracer uptake
in ROIs according to the following formula: abs((right
side/left side))-1 × 100. Quantitative assessments of
MRI data were not done because patients were imaged
at different magnet strengths.
Pittsburgh compound B status
PIB scans from CBS patients were visually rated as posi-
tive or negative for cortical uptake (by WJJ or GDR)
blinded to all other clinical data [18]. Each patient was
classified as CBS-PIB positive (CBS-PIB+) or CBS-PIBns. FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET,
Table 3 Comparison of methods versus PIB-PET results
Criteria FDG-Qual FDG-Quant MRI
Number 25 23 22 24
True negative 10 6 7 6
True positive 9 10 9 8
False negative 2 1 1 3
False positive 4 6 5 7
Accuracy 0.76 0.70 0.73 0.58
Rater confidence rating 44% 74% N/A 54%
Criteria =modified clinical criteria; True Negative = number of patients categorized
as fvCBS who were PIB negative; True Positive = number of patients categorized as
tpvCBS who were PIB positive; False Negative = number of patients categorized
as fvCBS who were PIB positive; False Positive = number of patients categorized
as tpvCBS who were PIB negative; Accuracy = True Negative + True Positive/total
Number; Confidence Rating = number of highly confident/total number of
patients; FDG-Qual, fluorodeoxyglucose PET qualitative (visual assessment);
FDG-Quant, fluorodeoxyglucose PET quantitative (computed using ROI); MRI,
magnetic resonance imaging; N/A, not applicable; PET, positron emission
tomography; ROI, region of interest.
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PET and structural MRI were compared to the PIB-PET
status as the gold standard for the presence or absence
of significant amyloid burden.
Voxel-wise group comparisons
To reproduce group-level differences in the anatomic
pattern of neurodegeneration previously observed in
autopsy-proven patients of AD and FTLD pathology [7],
we compared FDG patterns in CBS-PIB+ and CBS-PIB-
compared to NC and to each other. Voxel-wise compari-
sons of FDG SUVR images were performed in SPM8
using an analysis of covariance model that included
diagnosis (controls, CBS-PIB+, CBS-PIB-) as the condi-
tion, and age, sex and education as covariates. Pairwise
contrasts were performed among the three groups as
follows: CBS-PIB+ < NC, CBS-PIB- < NC, CBS-PIB+ >
CBS-PIB-, and CBS-PIB- > CBS-PIB+. Resulting T-maps
were displayed on an MNI template brain at a threshold
of P <0.001, uncorrected for multiple comparisons.
Statistical analysis
Group differences in dichotomous variables were com-
pared using Chi-square or Fisher’s exact test. Group differ-
ences in continuous variables were evaluated using
analysis of variance with post hoc Gabriel’s procedure or
Games-Howell procedure, depending on variance of data.
For non-parametric data, Mann–Whitney tests were ap-
plied for comparisons between two groups and Kruskal-
Wallis tests for three groups. Intra-rater reliability was
measured using Cohen kappa statistic. Sensitivity, specifi-
city, and positive and negative predictive values were esti-
mated by the appropriate observed proportion and 95%
confidence intervals were generated based on the assump-
tion that they follow a binomial distribution. Odds ratio
(OR) was employed to determine increased risk of PIB
positivity for clinical criteria. Statistical analysis was imple-
mented in Predictive Analytics SoftWare 20.0 (SPSS Inc.).
Results
Demographics
Patients and controls were matched for education and
sex (Table 2). There was a trend for older age at the time
of PET in the control group due to the older targeted
age recruitment for controls at our center. Patients were
more impaired than controls (Mini Mental State Exam
(MMSE)), but there were no differences between CBS-
PIB+ and CBS-PIB- (MMSE, Clinical Dementia rating).
Six of ten CBS-PIB+ but only one of ten CBS-PIB- pa-
tients carried the apolipoprotein E ε4 allele (P = 0.029).
CBS criteria
All patients met CBS criteria for either fv or tpv. Nineteen
patients met fvCBS criteria, eighteen met tpvCBS criteriaand twelve met criteria for both, requiring a designation
by the clinician (see Additional file 1: Table S1). Thirteen
patients had a final designation of tpv and twelve had fv.
Five of 12 and 5/13 were given highly confident ratings for
fvCBS and tpvCBS, respectively. There were no differences
in confidence ratings between the two groups.
Eleven patients were PIB+ and fourteen were PIB- by
blinded visual read. tpvCBS criteria had a sensitivity of
82% and a specificity of 71% for PIB+ status (Table 3)
for all CBS patients, regardless of confidence ratings. In
examining individual criteria within the variants, cogni-
tive testing had the strongest association with PIB
status, with OR of 8.1 for PIB+ in tpvCBS (episodic
memory/visuospatial impairment greater than executive
dysfunction) and OR of 6.4 for PIB- in fvCBS (executive
dysfunction greater than memory/visuospatial impair-
ment, P <0.05 for both). No other individual criterion
was significantly associated with PIB results. There were
no significant differences on individual neuropsycho-
logical measures when comparing CBS-PIB+ and CBS-
PIB- at the group level. There was a trend (P = 0.08) for
worse performance on the Benson figure copy in the
CBS-PIB+ group and a trend (P = 0.07) for greater im-
pairment in phonemic fluency in the CBS-PIB- group
(see Additional file 2: Table S2). In patients who under-
went ApoE genotyping, the presence of an ApoE4 allele
was 90% specific but only 60% sensitive for PIB-
positivity.
Imaging
Structural MRI was available on all but one patient and
FDG-PET was available on 23 (quantitative FDG-PET
available on 22, one scan was excluded due to different
PET scanner type and quantitative results were not dir-
ectly comparable). The sensitivity of visual MRI reads
Sha et al. Alzheimer's Research & Therapy  (2015) 7:8 Page 6 of 12for PIB+ status was 73% and specificity was 46%. Quan-
titative and qualitative readings of FDG-PET both
yielded a sensitivity of 91% and similar specificities (58%
and 50%, Table 3). Intra-rater reliability of FDG-PET
qualitative reading was perfect (κ = 1.00) while MRI
intra-rater reliability was modest (κ = 0.42). Confidence
rating was highest for FDG-PET and lowest for clinical
criteria, although these differences were not significant.
The combination of tpvCBS criteria and temporoparietal-
predominant qualitative FDG-PET was a strong predictor
for CBS-PIB+ (P = 0.005, OR 22.5 (95% confidence interval
2.6 to 194.5); see Additional file 3: Table S3). Combined
tpvCBS criteria and temporoparietal-predominant MRI
also predicted CBS-PIB+ (P <0.05, OR 9.6 (95% confi-
dence interval 1.378 to 67.2); see Additional file 3:
Table S3, which provides ORs for clinical criteria alone
and in combination with FDG-PET and MRI for pre-
dicting PIB positivity and negativity).
At a group level, the CBS-PIB+ and the CBS-PIB-
cohorts both demonstrated hypometabolism compared
with controls in peri-rolandic/posterior frontal regions
on voxel-wise comparisons (left sided in CBS-PIB-,
bilateral in CBS-PIB+, P <0.001 uncorrected, Figure 2).
Decreased metabolism in both groups was noted in the
caudate nucleus, although this signal should be inter-
preted with caution since these results may be, at least
in part, due to ventricular enlargement in CBS patientsFigure 2 Voxel-wise FDG comparisons. Patterns of hypometabolism in CB
with each other. Voxel-wise comparisons included sex, education and age as
All results are presented at a threshold of P <0.001, uncorrected for multip
negative; CBS-PIB+, corticobasal syndrome Pittsburgh compound B positive; Fversus controls. Hypometabolism in CBS-PIB+ extended
into bilateral temporoparietal cortex.
On direct comparison of patient groups, hypometabo-
lism was greater in the CBS-PIB- in a small cluster in
the midline superior cerebellum, and greater in the
CBS-PIB+ group in extensive regions of right temporo-
parietal cortex (Figure 2).
The CBS-PIB+ group had lower glucose metabolism
than normal controls in the bilateral ‘common’ and tem-
poroparietal and right frontal ROIs. The CBS-PIB- group
had decreased uptake compared to controls in the bilat-
eral ‘common’, left frontal and left temporoparietal ROIs
(Table 4). CBS-PIB+ had greater hypometabolism than
CBS-PIB- in the right temporoparietal ROI.
FDG-PET LIs are shown in Table 4. CBS-PIB+ and the
CBS-PIB- both showed greater lateralization of FDG
uptake compared to controls in all ROIs, but there was
no difference in lateralization between CBS-PIB+ and
CBS-PIB-.
Pathology
Autopsy (N = 7) or biopsy (N = 1) results were consistent
with PIB-PET findings during life (Table 5). PIB-PET
scans were positive in two patients who met criteria for
both high probability AD (NIA-Reagan criteria) and
intermediate probability Lewy body disease (McKeith
criteria) [21,23]. A third CBS-PIB+ patient was found toS-PIB- and CBS-PIB+ compared with normal controls (NC) and compared
nuisance variables. T-score maps are rendered on the ch2.better template.
le comparisons. CBS-PIB-, corticobasal syndrome Pittsburgh compound
DG, fluorodeoxyglucose.





NC (number = 26) P Post hoc
FDG-common, z −1.89 ± 0.81 −1.69 ± 1.37 0.00 ± 1.00 0.000 CBS-PIB+ versus NC P <0.001, CBS-PIB- versus
NC P <0.001
right −2.29 ± 0.89 −1.48 ± 1.66 0.00 ± 1.00 0.000 CBS-PIB+ versus NC P <0.001, CBS-PIB- versus
NC P <0.01
left −1.59 ± 0.91 −1.91 ± 1.30 0.00 ± 1.00 0.000 CBS-PIB+ versus NC P <0.001, CBS-PIB- versus
NC P <0.001
LI 10.42 ± 4.37 8.82 ± 5.99 2.83 ± 1.72 0.000 CBS- PIB+ versus NC P <0.001, CBS-PIB- versus
NC P <0.014
FDG-frontal, z −1.26 ± 0.91 −1.06 ± 1.61 0.00 ± 1.00 0.005 CBS-PIB+ versus NC P <0.05, CBS-PIB- versus
NC P <0.05
right −1.51 ± 0.94 −0.83 ± 1.55 0.00 ± 1.00 0.002 CBS-PIB+ versus NC P <0.01
left −1.00 ± 0.92 −1.30 ± 1.84 0.00 ± 1.00 0.008 CBS-PIB- versus NC P <0.05
LI 6.53 ± 3.08 10.52 ± 8.16 1.70 ± 1.33 0.000 CBS- PIB+ versus NC P <0.002, CBS-PIB- versus
NC P <0.008
FDG-temporoparietal, z −2.76 ± 1.65 −0.93 ± 1.65 0.00 ± 1.00 0.000 CBS-PIB+ versus CBS-PIB- P <0.01, CBS-PIB+
versus NC P <0.001
right −3.22 ± 2.12 −0.65 ± 1.84 0.00 ± 1.00 0.000 CBS-PIB+ versus CBS-PIB- P <0.05, CBS-PIB+
versus NC P <0.05
left −2.20 ± 1.38 −1.06 ± 1.56 0.00 ± 1.00 0.000 CBS-PIB+ versus NC P <0.001, CBS-PIB- versus
NC P <0.05
LI 13.10 ± 8.20 8.45 ± 6.95 2.00 ± 1.41 0.000 CBS- PIB+ versus NC P <0.005, CBS-PIB- versus
NC P <0.021
CBS-PIB+, corticobasal syndrome positive for Pittsburgh compound B; CBS-PIB-, corticobasal syndrome negative for Pittsburgh compound B; FDG, fluorodeoxyglucose;
LI, lateralization index; NC, normal control; ROI, region of interest. Data are mean ± standard deviation.
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opsy (with vascular brain injury as a contributing diagno-
sis). This patient had frequent neocortical neuritic plaques
(CERAD score) and neurofibrillary tangles (Braak Stage
VI) accompanied by tau-positive glial cytoplasmic inclu-
sions (astrocytes and oligodendroglia) and subcortical
white matter pathology consistent with CBD (Figure 3).
CBD pathology was more restricted in topographical dis-
tribution than the widespread AD pathology, leading the
pathologist to consider AD as the primary pathological
diagnosis and CBD as a contributing secondary pathology.Table 5 Pathology results in comparison to other methods of
Patient PIB-PET Pathology Criteri
2 - CBD fvCBS
3 - CBD fvCBS
8 - CBD tpvCBS
10 - PSP fvCBS
14 - Pick’s + DLB tpvCBS
13 + AD + CBDa tpvCBS
18 + AD + DLB tpvCBS
19 + AD + DLB tpvCBS
aPatient 13 had evidence of AD and CBD pathology, but AD was the predominant p
frontal variant corticobasal syndrome; FDG-Qual, fluorodeoxyglucose PET qualitative
PET quantitative (computed using ROI); PET, positron emission tomography; PSP, pr
variant CBS. A ‘+’ or ‘-’ indicates positive or negative, respectively.PIB-PET scans were negative in three patients with
pathologically confirmed CBD, one with progressive
supranuclear palsy (PSP) and one with both Pick’s
disease and LBD.
Discussion
This study evaluated the utility of clinical criteria, FDG-
PET and structural MRI in predicting the PIB-PET findings
in 25 patients meeting core clinical criteria for CBS. Prior
studies have assessed correlates of pathology in CBS at
a group level, but our goal was to identify distinguishingassessment









athology. AD, Alzheimer’s disease; CBD, corticobasal degeneration; fvCBS,
(visual assessment); LBD, Lewy body disease; FDG-Quant, fluorodeoxyglucose
ogressive supranuclear palsy; ROI, region of interest; tpvCBS, temporoparietal
Figure 3 Neuropathology of patient 13. A. Angular gyrus immunostained against beta-amyloid (4G8). Arrows indicate neuritic plaques and
arrowhead indicates cerebral amyloid angiopathy, a typical finding in Alzheimer’s disease patients (Scale bar: 250 μm); B. Inferior temporal gyrus
immunostained against phospho-tau (CP-13). The arrows point to neurofibrillary tangles, characteristic of AD. Note their flame-like shape (Scale
bar: 500 μm); C. Precentral gyrus immunostained against phospho-tau (CP-13). Arrows indicate ballooned neurons in the cortical deep layers,
commonly seen in CBD (Scale bar: 500 μm); D. Precentral gyrus immunostained against phospho-tau (CP-13). The line divides the cortex to the
right (cx) and the white matter to the left (WM). Note the striking positivity of white matter for phospho-tau, a feature seen in CBD but not in
other tauopathies or AD. AD, Alzheimer’s disease; CBD, corticobasal degradation.
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able to clinicians. FDG-PET (qualitatively and quantita-
tively) had the best sensitivity (approximately 90%) for
predicting PIB+ status and proposed clinical criteria for
tpvCBS had the best specificity (71%). Visual interpret-
ation of structural MRI fared the worst and was not
useful in determining PIB-status when used alone.
Combining clinical tpvCBS criteria (specific) with FDG-
PET (sensitive) yielded the best overall discrimination
of PIB+ versus PIB- CBS patients.
Our proposed criteria offered diagnostic utility, yield-
ing 76% classification accuracy. Sensitivity of tpvCBS
criteria for CBS-PIB+ was high (82%), although specifi-
city was modest (71%), suggesting that these criteria
require further refinement. One main issue was diffi-
culty in operationalization. Many patients met criteria
for both variants, requiring clinical judgment for
categorization. Not surprisingly, there was high confi-
dence in fewer than half of patients. The individual
criterion that was the best predictor of PIB status was
the pattern of cognitive impairment. An executive-
predominant pattern predicted PIB- and a memory/
visuospatial predominant pattern predicted PIB+ status,
mirroring results from group-level comparisons ofautopsy-proven patients of CBS-FTLD versus CBS-AD
[7,9]. In contrast to previous studies, non-fluent aphasia
and behavioral presentations did not predict negative PIB.
This may be due to the heterogeneous pathologies that
likely underlie CBS-PIB-, including CBD, PSP and FTLD-
TDP. Parietal features included in our tpvCBS criteria
(for example, Gerstmann syndrome) also lacked predict-
ive power, perhaps reflecting the proclivity of both AD
and non-AD pathology to affect dorsolateral parietal
cortex in CBS. In our cohort, anatomical overlap be-
tween PIB+ and PIB- patients was greater in the left
parietal lobe than in right parietal or bilateral temporal
cortex (Figure 2), consistent with the greater predictive
power of visuospatial and episodic memory loss com-
pared to dominant parietal features and reflected by the
trend for worse performance on the Benson figure copy
seen in the CBS-PIB+ cohort. Although asymmetry of
clinical symptoms, imaging analyses and cognitive re-
sults are inherent in CBS, asymmetry is not predictive
of underlying pathology, also noted in a prior study by
our center [7].
An expert international group has recently proposed
new diagnostic criteria for CBD [14]. The goal of these
criteria differs from ours in a subtle, but important way:
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types predictive of CBD pathology, whereas we tested
clinical features predictive of AD pathology in CBS
patients. Unfortunately, the new criteria were published
after completion of the chart review phase of our study,
such that we were not able to test their reliability in
identifying PIB-negative patients prospectively and in
blinded fashion. Our core CBS criteria overlapped with
Armstrong et al.’s for ‘probable CBS’ although we did
not require asymmetry or apraxia as core diagnostic
elements (however, lower limb apraxia which may have
better anatomic specificity, was included in the frontal
variant). The high prevalence of PIB+ patients in our
cohort (44%) underscores the need to refine the defin-
ition of CBS in criteria that strive to be specific
for underlying CBD. Notably, the Armstrong criteria
recognize a ‘frontal behavioral-spatial’ syndrome and
modified criteria from Cambridge also propose to
lump together executive and visuospatial deficits as
core cognitive features of CBS [32]. Our data suggest
that the relative involvement of executive versus
visuospatial dysfunction is a strong predictor of AD
versus non-AD underlying neuropathology and these
domains should be split in criteria that aim to predict
underlying pathology in CBS.
Another important finding in our study was the ability
to improve the prediction of PIB status for the individual
by assessing whether the neurodegenerative pattern is pre-
dominantly frontal or temporoparietal on MRI or FDG-
PET. FDG-PET showed high sensitivity for CBS-PIB+,
perfect intra-rater agreement in visual interpretations,
and high accuracy of visual reads versus quantitative
analysis. These findings are consistent with previous
studies demonstrating that FDG-PET is useful in differ-
entiating AD from FTLD [18,33]. The combination of
tpv-predominant clinical criteria and FDG-PET was
particularly powerful, predicting PIB+ status with an
OR of 22.5. In lieu of access to amyloid imaging or other
biomarkers, FDG-PET may be a useful ancillary test for
differentiating pathologies in CBS. However, a temporo-
parietal pattern on FDG was not specific for PIB+ scans.
While frontal-predominant hypometabolism is uncom-
mon in CBS patients with AD, a temporoparietal-
predominant pattern does not exclude the possibility of
non-AD pathology. Visual interpretation of MRI atro-
phy patterns proved less helpful. Quantitative MRI mea-
sures would likely have performed better, but were not
included in this study because patients underwent MRI
on 1.5 T, 3 T and 4 T scanners. Our study suggests that
structural and functional imaging markers can improve
diagnostic accuracy when supplementing clinical criteria
and may prove useful in future iterations of criteria.
Although the aim of this study was to determine
predictors of PIB-PET status for the individual, we alsoperformed voxel-wise and specific ROI group analyses.
Our findings comparing CBS-PIB+ with CBS-PIB- were
similar to prior reports contrasting autopsy-confirmed
patients of CBS-AD versus CBS-FTLD [7,10,11,34,35].
CBS-PIB+ had greater temporoparietal hypometabolism
than CBS-PIB-, and both groups showed hypometabolism
in posteromedial frontal and peri-rolandic cortex, regions
that comprise a sensorimotor integration network [36].
This network may be the core affected network in all
patients with the CBS phenotype, independent of
underlying pathology. The contrast CBS-PIB- < CBS-
PIB+ did not yield a characteristic FDG pattern, likely
due to the heterogeneous pathologies represented in
this group. Interestingly, we found greater hypometabo-
lism in CBS-PIB- in the medial cerebellum, a region
often affected in PSP, which may be the second most
common cause of CBS [7]. Asymmetry did not distin-
guish CBS-PIB+ from CBS-PIB- and does not aid in
predicting pathology, consistent with our observations
in pathologically-confirmed CBS-AD and CBS-FTLD
[7]. However, as a group, CBS-PIB+ had a right-sided
bias for metabolic patterns and CBS-PIB- had a left
sided bias which may reflect the inclusion of non-fluent
variant primary progressive aphasia (PPA) patients in
the CBS-PIB- cohort.
Our study, as well as another study applying amyloid
PET in CBS [13], found similar clinical and anatomical
differences between CBS-PIB+ and CBS-PIB- to those
reported when comparing CBS-AD and CBS-FTLD in
clinicopathological studies, providing preliminary valid-
ation for the use of amyloid imaging as an in vivo proxy
for AD pathology in CBS. However, as illustrated by one
of our autopsy-proven patients, a positive amyloid PET
scan does not exclude the presence of CBD or another
meaningful co-pathology, although in this case CBD was
considered secondary to AD in driving the clinical syn-
drome of CBS. In fact, ratings were tpvCBS on all
methods of assessment suggesting underlying AD path-
ology. Importantly, significant neuritic plaques (and
positive amyloid PET) can also be seen in 15% to 30% of
cognitively normal older individuals [37]. Therefore,
while a negative amyloid scan ‘rules out’ AD with high
likelihood in patients presenting with CBS, a positive
scan does not exclude a co-pathology that may be the
primary etiology of symptoms, particularly in patients
with frontal features which are most strongly associated
with underlying FTLD pathology.
Aside the from lack of pathological confirmation in
some patients, limitations of our study include the rela-
tively small sample size (although our cohort was similar
in size to previous studies of CBS which is an uncom-
mon syndrome) and the retrospective chart and imaging
review by a single rater. It is possible that there was a
referral bias to our cognitive clinic, rather than a
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search group receives primary movement disorders pa-
tient referrals, particularly to our cohort research
studies. Additionally, this study was designed to build
upon our prior study [7] that found the nature of sever-
ity of the movement disorder did not distinguish AD
from FTLD, stressing the importance of a multi-
disciplinary approach to the evaluation of CBS. The cri-
teria for each variant were based on our review of the
literature and were not intended to provide final or vali-
dated criteria. Rather, this study was designed to exam-
ine whether splitting CBS into clinical variants could
improve our ability to predict PIB status. A similar
approach has been fruitful in PPA [16]. The criteria pre-
sented here can, therefore, be considered a foundation
upon which to build future consensus criteria. While the
future evaluation of CBS may incorporate molecular bio-
markers for amyloid beta (Aβ), tau [38] and TDP-43
[39], even the most validated of these markers (cerebro-
spinal fluid Aβ and tau and amyloid PET) are not yet
accessible in routine clinical practice despite a decade or
more of research. Tau PET scans are the subject of
current research [38] and will likely be incorporated in
the future with amyloid PET to predict pathology for the
individual patient. Possible implications include inclu-
sion/exclusion criteria for clinical trials, ruling out
co-pathology, or biomarker progression of disease. De-
termining the presence of co-pathology with amyloid
potentially could alter treatment efficacy or disease
course of a patient and would be important to note
when analyzing results of a study or trial. For the mo-
ment, access to these markers is largely confined to the
research realm, where they can be applied to refine
clinical criteria and optimize the integration of more
accessible tools, such as MRI and FDG-PET, into the
diagnostic assessment of CBS and other heterogeneous
disorders [40].
Conclusions
This study was not designed to identify cost-effectiveness,
but it examined approaches to optimize suspected
underlying pathologies to support the potential of spe-
cific targeted treatment. Our data suggest that there is
current diagnostic value in ‘splitting’ CBS patients into
those presenting with predominant frontal features
(who are likely to have underlying FTLD pathology) and
those with predominant temporoparietal features (which
are highly sensitive although not specific for underlying
AD). The predictive value can be enhanced by classifying
the predominant pattern of neurodegeneration on neuro-
imaging. In practice, MRI is the standard of care and
will likely be acquired in most patients. However, in our
studies atrophy patterns on MRI were often hard to
classify with confidence as ‘frontal’ or ‘temporoparietal’predominant. In such uncertain cases, the addition of
FDG-PET can be diagnostically useful. As molecular im-
aging is increasingly validated and accessible, future
diagnostic algorithms in CBS will likely include a com-
bination of amyloid and tau PET in addition to clinical
assessment and MRI. This combination should allow
the in vivo classification of CBS due to AD, primary
tauopathy and (by process of elimination) FTLD-TDP
pathology with high certainty, paving the way for the
development and ultimate implementation of protein-
specific therapies.
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